CN
News & Events
PhIRDA Delegation Visited WHO
News & Events 2017.08.08 609

On June 27, led by Dr. Ding Lieming, Chairman of PhIRDA, Chairman & CEO of Betta Pharmaceuticals, and Prof. Song Ruilin, Executive President of PhIRDA, PhIRDA Delegation visited the headquarter of World Health Organization (WHO). Dr. Ren Minghui, Assistant Director-General of WHO, Dr. Dirk Engels, Director, Department of Control of Neglected Tropical Disease, Dr. Karin Weyer, Coordinator of Laboratories, Diagnostics and Drug Resistance Global TB Programme, Dr. Daniel Low-Beer, Coordinator, Strategic Information and Planning, department of HIV/AIDS, Dr. Sabine Kopp, Group Lead of Medicine Quality Assurance Technologies Standards and Norms met with PhIRDA Delegation and had a productive meeting.

Dr. Ren Minghui expressed warm welcome to the visit of PhIRDA Delegation, and introduced the structure and function of WHO. Business sectors include financial budget and administrative management division, noncommunicable diseases division, infectious diseases division, control of neglected tropical diseases division, women and children protection division, emergency division, health and innovation essential drugs division and antibiotic resistance (AMR) secretariat as well.

Dr. Ding Lieming made a brief introduction of PhIRDA and the delegation. He said that as a non-profit social organization, PhIRDA is committed to promoting pharmaceutical innovation. The main purpose to visit WHO is to learn more about what Chinese pharmaceutical industry could do for the whole world. The Initiative Belt and Road Policy made China to take more responsibility; Chinese pharmaceutical industry is expected to do more to improve global health level as well.

During the meeting, representatives from PhIRDA and WHO discussed questions on how to solve drug availabilities, antibiotic resistance, infectious diseases, neglected tropical disease, local production of drugs, tuberculosis drugs and testing.

Executive President Song Ruilin expressed that WHO is exploring the linkage between Prequalification Programme and national drugs registration together, and China is expected to do more contribution and play a crucial role during this process.